A provocative article on the front page of the Sunday’s New York Times (April 6, 2014) took on the high cost of diabetes care and investigated several areas of medical advancements as well as outrageous pricing. The article asks startling questions such as: Are your favorite diabetes drugs and devices relevant to your treatment?
DexCom and Tandem Diabetes Care have a CGM Development and Commercialization Agreement to integrate the Dexcom's future generation sensor into the t:slim Insulin Delivery System. The t:slim, the first touch-screen insulin pump, has FDA approval but is not on the market yet. The announcement also mentions "future generations of the sensor", so it may be awhile before we see the systems actually working together.
Medtronic received FDA approval to sell the mySentry Remote Glucose Monitor in the U.S. on January 4, 2012. This remote monitor allows the parents of a child with diabetes to see their child’s continuous glucose monitor (CGM) data during the night from a Paradigm Revel insulin pump while they sleep in another room.
Dexcom is making more friends. Already having partnerships with Animas and Omnipod, Dexcom has now signed a research and development agreement with Roche Diagnostics U.S. The plan is to integrate Dexcom's continuous glucose monitor into Roche's insulin pumps so you can see trends and blood glucose data in one handheld device.
Here's an excerpt from the announcement:
The Dexcom STS and the Paradigm RT continuous monitors are currently available in the U.S. with a prescription. In this study, they are compared head to head while being worn by one person with Type 1 diabetes. Over 33 days, 262 simultaneous readings were compared between a One Touch meter and the two continuous monitors. The meter was used to calibrate both monitors and as the standard against which their accuracy was evaluated.